CADTH Canadian Drug Expert Committee recommendation: Netupitant/palonosetron (Akynzeo -- Purdue Pharma) indication : chemotherapy-induced nausea and vomiting
The CADTH Canadian Drug Expert Committee (CDEC) recommends that netupitant/palonosetron, in combination with dexamethasone, be reimbursed for once-per-cycle treatment in adult patients for prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy (HEC)...
Corporate Authors: | , |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
CADTH
2018, June 20, 2018
|
Edition: | Final |
Series: | CADTH common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that netupitant/palonosetron, in combination with dexamethasone, be reimbursed for once-per-cycle treatment in adult patients for prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy (HEC), if the following criterion and condition are met: reimburse in a manner similar to aprepitant within drug plans that already reimburse aprepitant for the prevention of nausea and vomiting associated with HEC. |
---|---|
Physical Description: | 1 PDF file (7 pages) |